Literature DB >> 17501702

11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA.

Martin Braddock1.   

Abstract

The Strategic Research Institute (SRi) hosted the 11th International Inflammation and Immune Diseases Drug Discovery and Development World Summit in San Francisco during 12-13 March 2007. The summit comprised keynote sessions and two parallel tracks and focussed on targeting mechanisms for drug discovery and development, which modulate the immune response and which have anti-inflammatory activity in a number of human diseases. Indications included psoriasis, hepatitis C, allergic dermatitis, systemic lupus erythematosus, rheumatoid arthritis and osteoarthritis, multiple sclnerosis, cardiovascular disease and asthma. Data were presented supporting all stages of drug discovery from target identification and validation through to lead identification and optimisation to both early- and late-stage clinical development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17501702     DOI: 10.1517/13543784.16.6.909

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

1.  Interleukin-6 cytokine: a multifunctional glycoprotein for cancer.

Authors:  Paul Zarogoulidis; Lonny Yarmus; Kaid Darwiche; Robert Walter; Haidong Huang; Zhigang Li; Bojan Zaric; Kosmas Tsakiridis; Konstantinos Zarogoulidis
Journal:  Immunome Res       Date:  2013-08-12

Review 2.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

3.  Anti-inflammatory and antioxidant effects of an ethanolic extract of the aerial parts of Hilleria latifolia (Lam.) H. Walt. (Phytolaccaceae).

Authors:  W K M Abotsi; G K Ainooson; E Woode
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-10-02

4.  I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.

Authors:  Ayad Al-Katib; Alan A Arnold; Amro Aboukameel; Angela Sosin; Peter Smith; Anwar N Mohamed; Frances W Beck; Ramzi M Mohammad
Journal:  Mol Cancer       Date:  2010-09-01       Impact factor: 27.401

5.  Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.

Authors:  Ken Tawara; Julia T Oxford; Cheryl L Jorcyk
Journal:  Cancer Manag Res       Date:  2011-05-18       Impact factor: 3.989

6.  Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.

Authors:  Sheila Ranganath; Ashok Bhandari; Nicole Avitahl-Curtis; Jaimee McMahon; Derek Wachtel; Jenny Zhang; Christopher Leitheiser; Sylvie G Bernier; Guang Liu; Tran T Tran; Herodion Celino; Jenny Tobin; Joon Jung; Hong Zhao; Katie E Glen; Chris Graul; Aliesha Griffin; Wayne C Schairer; Carolyn Higgins; Tammi L Reza; Eva Mowe; Sam Rivers; Sonya Scott; Alex Monreal; Courtney Shea; Greg Bourne; Casey Coons; Adaline Smith; Kim Tang; Ramya A Mandyam; Jaime Masferrer; David Liu; Dinesh V Patel; Angelika Fretzen; Craig A Murphy; G Todd Milne; Mark L Smythe; Kenneth E Carlson
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.